SCPHbenzinga

scPharmaceuticals Reports Preliminary Q4 Revenue Of $12M-$12.3M; FY24 Revenue Expected To Be $36.2M-$36.5M

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on January 10, 2025 by benzinga